Lupin Rationalizes Japan Operations, Sheds Injectables Business
Lupin sells Japanese injectables business, eight years after it made an acquisition in that segment there. The Indian firm now plans to concentrate on building a hybrid pharma model in the country.
You may also be interested in...
Pricing pressure in Japan is expected to weigh significantly on growth even in the generics segment, putting the focus on manufacturing and R&D efficiencies to sustain progress in this market, according to senior Lupin executives.
Lupin continues to make niche buys internationally, this time acquiring the Toyko-based specialty injectables firm, I’rom Pharmaceutical Co, for an undisclosed sum.
Big pharma R&D leaders discuss the confluence of technology and biotech driving insights into biology and how industry is doing in terms of identifying patients earlier in disease.